Delphia (USA)’s Kura Oncology KURA Stock Holding History

Delphia (USA)’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,430	Closed	-$210K	–	361
2022 Q2	$210K	Buy	+11,430	New	+$164K	0.14%	269

Other funds holding KURA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Delphia (USA)'s KURA Position: Q3 2022 in Review

Delphia (USA) sold out of Kura Oncology (KURA) in Q3 2022, closing a stake of 11,430 shares — an estimated $210K sold.

Delphia (USA) first reported a position in KURA in Q2 2022 and held it in 1 quarter. The position peaked at $210K in Q2 2022. 148 funds tracked by Wall St. Rank hold KURA as of Q3 2022.

Delphia (USA) reported no remaining Kura Oncology position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 11,430 Kura Oncology shares in Q3 2022, an estimated $210K.
Delphia (USA) first reported a position in Kura Oncology in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Kura Oncology position peaked at $210K in Q2 2022.
148 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.